Lemborexant Shift Work Treatment Study

Authors University of California, San Francisco -More
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Links ClinicalTrials.gov
Insomnia and daytime sleepiness are common complaints among night shift workers, but effective sleep treatments in shift workers are lacking. The aim of this Phase IV double-blind, placebo-controlled, randomized study is to test whether a dual orexin antagonist, Lemborexant (5mg or 10mg), which would be expected to block the clock-driven orexin-mediated wakefulness during the day, will increase daytime sleep time in shift workers who complain of difficulty sleeping during the daytime compared to placebo.
Epistemonikos ID: 8fde407c298e4e0085449a431aac66eda8e7d3ba
First added on: May 13, 2024